» Articles » PMID: 32366708

Manogepix (APX001A) Displays Potent Activity Against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs

Overview
Specialty Pharmacology
Date 2020 May 6
PMID 32366708
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Manogepix (APX001A) is the active moiety of the novel drug candidate fosmanogepix (APX001). We previously reported the broad-spectrum activity of manogepix but also observed a correlation between increased manogepix and fluconazole MICs. Here, we extended this study and included isolates with acquired fluconazole resistance. Isolates ( = 835) were identified using CHROMagar, matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), and, when needed, internal transcribed spacer (ITS) sequencing. EUCAST E.Def 7.3.1 susceptibility testing included manogepix, amphotericin B, anidulafungin, micafungin, fluconazole, and voriconazole. Manogepix wild-type-upper-limit (WT-UL) values were established following EUCAST principles for the epidemiological cutoff value (ECOFF) setting allowing wild-type/non-wild-type classification. Drug-specific MIC correlations were investigated using Pearson's correlation. Manogepix modal MICs were low (range, 0.004 to 0.06 mg/liter against 16/20 included species). Exceptions were and and, to a lesser extent, and The activity was independent of Fks echinocandin hot spot alterations ( = 17). Adopting the WT-UL established for , , , , and , 14/724 (1.9%) isolates were non-wild type for manogepix. Twelve of these (85.7%) were also non-wild type for fluconazole. A statistically significant correlation was observed between manogepix and fluconazole MICs for , , , , and (Pearson's  = 0.401 to 0.575) but not between manogepix and micafungin or amphotericin B MICs for any species except ( = 0.519 for manogepix versus micafungin). Broad-spectrum activity was confirmed for manogepix against contemporary yeast. However, a 1 to 4 2-fold dilutions increase in manogepix MICs is observed in a subset of isolates with acquired fluconazole resistance. Further studies on the potential underlying mechanism and implication for optimal dosing are warranted.

Citing Articles

mutation in decreases manogepix susceptibility owing to increased expression.

Hirayama T, Miyazaki T, Tanaka R, Kitahori N, Yoshida M, Takeda K Antimicrob Agents Chemother. 2024; 69(2):e0150824.

PMID: 39692503 PMC: 11823642. DOI: 10.1128/aac.01508-24.


A Mini-Review of In Vitro Data for Species, Including Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin.

Espinel-Ingroff A, Wiederhold N J Fungi (Basel). 2024; 10(5).

PMID: 38786717 PMC: 11122255. DOI: 10.3390/jof10050362.


Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.

Hoenigl M, Arastehfar A, Arendrup M, Bruggemann R, Carvalho A, Chiller T Clin Microbiol Rev. 2024; 37(2):e0007423.

PMID: 38602408 PMC: 11237431. DOI: 10.1128/cmr.00074-23.


activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022).

Pfaller M, Huband M, Bien P, Carvalhaes C, Klauer A, Castanheira M Antimicrob Agents Chemother. 2024; 68(2):e0113223.

PMID: 38205999 PMC: 10848754. DOI: 10.1128/aac.01132-23.


The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo.

Konings M, Eadie K, Strepis N, Nyuykonge B, Fahal A, Verbon A Med Mycol. 2023; 61(11).

PMID: 37960934 PMC: 10684268. DOI: 10.1093/mmy/myad118.


References
1.
Kapoor M, Moloney M, Soltow Q, Pillar C, Shaw K . Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Species. Antimicrob Agents Chemother. 2019; 64(1). PMC: 7187586. DOI: 10.1128/AAC.01387-19. View

2.
Arendrup M, Chowdhary A, Astvad K, Jorgensen K . APX001A Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method. Antimicrob Agents Chemother. 2018; 62(10). PMC: 6153824. DOI: 10.1128/AAC.01225-18. View

3.
Arendrup M, Meletiadis J, Mouton J, Guinea J, Cuenca-Estrella M, Lagrou K . EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin Microbiol Infect. 2016; 22(6):571.e1-4. DOI: 10.1016/j.cmi.2016.01.017. View

4.
Jensen R, Johansen H, Soes L, Lemming L, Rosenvinge F, Nielsen L . Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study. Antimicrob Agents Chemother. 2015; 60(3):1500-8. PMC: 4775986. DOI: 10.1128/AAC.01763-15. View

5.
Arendrup M, Patterson T . Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment. J Infect Dis. 2017; 216(suppl_3):S445-S451. DOI: 10.1093/infdis/jix131. View